Skip to content

Intra-operative evaluation of efficacy and safety of a new lead for steering Deep Brain Stimulation.

Intra-operative evaluation of efficacy and safety of a new lead for steering Deep Brain Stimulation. First Acute-in-Man Evaluation of Steering Brain Stimulation.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON20700
Enrollment
10
Registered
2012-10-08
Start date
2012-10-22
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease, Deep Brain Stimulation Ziekte van Parkinson, Diepe Hersenstimulatie

Interventions

Sapiens Deep brain stimulation lead.

Sponsors

Sapiens Steering Brain Stimulation B.V. H.C.F. Martens, PhD Director of Clinical Science High Tech Campus 48 5656 AE Eindhoven The Netherlands Tel: +31 40 800 2104
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Diagnosis of idiopathic Parkinson's disease; 2. Clinical indication for STN DBS with MER; 3. Age > 18 years; 4. Subject is a male or non-pregnant female; 5. Ability to comply with the study assignments; 6. Ability to give informed consent.

Exclusion criteria

Exclusion criteria: 1. Parkinson's disease graded according to Hoehn and Yahr stage 5; 2. Score on MATTIS dementia rating scale <120; 3. Psychiatric contraindications to STN DBS; 4. General contraindications for stereotactic surgery and general anaesthesia (e.g. severe hypertension, blood coagulation disorder); 5. Subject has factors that would put the subject at an additional risk for intra-operative or postoperative bleeding. This includes underlying disorders of the coagulation cascade (eg, hemophilia), disorders that affect platelet count or function (eg, Von Willebrand's disease), as well as administration of any anti-platelet or anti-coagulant medication in the 7 days prior to surgery, or any history of anticoagulant or aspirin use or history of hemorrhagic stroke, that in the view of the neurosurgeon or neurologist would place the subject at an increased risk for intra-operative or postoperative bleeding; 6. Subject has a diagnosis of acute myocardial infarction or cardiac arrest less than or equal to 6 months prior to the screening testing; 7. Subject has a history of a seizure disorder; 8. Subject requires short surgery time due to general health issues, as determined by the investigator; 9. Subject is a woman who is pregnant or planning to become pregnant, or a woman of child-bearing potential, who is not using a medically-acceptable method of birth control. Women of child-bearing potential must undergo a pregnancy test, with a clear negative result, no more than 7 days prior to the investigational procedure visit.

Design outcomes

Primary

MeasureTime frame
1. Description of and threshold for effects obtained by stimulation through Sapiens lead in standard mode; 2. Analysis of safety of stimulation with the Sapiens lead compared to control data.

Secondary

MeasureTime frame
1. Description of and threshold for effects obtained by stimulation through Sapiens lead in different modes; 2. Determination and comparison of "therapeutic window", obtained by stimulation through Sapiens lead in different modes.

Contacts

Public ContactP.R. Schuurman

Academic Medical Center (AMC), department of Neurosurgery, P.O. Box 22660

p.r.schuurman@amc.nl+31 (0)20 5669111

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)